UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Raises PT on Repros Therapeutics Following Positive Topline Results

Loading...
Loading...
In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on
Repros TherapeuticsRPRX
, and raised the price target from $23.00 to $25.00. In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study bodes well for a positive result from the ZA-304 study, given that the trials are identical in design. Further, we believe that positive results from these studies will also be valuable in supporting potential labeling claims for superiority of Androxal over Androgel, which would improve the commercial attractiveness of the product. Our 12 month PT is calculated using an NPV analysis.” Repros Therapeutics closed on Thursday at $18.21.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsAscendiant Capital MarketsKeay Nakae
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...